Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now
Key Stock Data
The current last sale of $72.46 is 52.55% Higher than the 52 week low.
|Intraday||Last 52 Weeks|
|High:||$ 75.22||$ 104.53|
|Low:||$ 71.90||$ 47.50|
Company Description (as filed with the SEC)
Reata's mission is to develop innovative therapies that change patients' lives for the better. We focus on developing small-molecule therapeutics with novel mechanisms of action for the treatment of severe, life-threatening diseases with few or no approved therapies. Our lead product candidates, bardoxolone methyl (Bard) and omaveloxolone (Omav), activate the transcription factor Nrf2, which plays an important role in regulating the cellular response to injury. By activating Nrf2, Bard and Omav normalize mitochondrial function, restore redox balance, and resolve inflammation. We have fully enrolled two registrational clinical trials: CARDINAL, studying Bard in chronic kidney disease (CKD) caused by Alport syndrome, and MOXIe, studying Omav in Friedreich's ataxia (FA). CKD caused by Alport syndrome and FA are rare, serious diseases with no approved therapy. ... More ...
Nasdaq Official Price
Aug. 23, 2019